Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

133.01USD
24 Jul 2017
Change (% chg)

$-2.30 (-1.70%)
Prev Close
$135.31
Open
$134.99
Day's High
$135.02
Day's Low
$132.86
Volume
2,656,033
Avg. Vol
1,927,191
52-wk High
$137.07
52-wk Low
$109.32

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.77
Market Cap(Mil.): $358,306.81
Shares Outstanding(Mil.): 2,693.83
Dividend: 0.84
Yield (%): 2.53

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.49 13.56 17.15
EPS (TTM): 5.91 -- --
ROI: -- -7.26 -5.60
ROE: -- -6.80 -4.89

Nasdaq, tech shine as earnings pick up; Dow, S&P lag

NEW YORK The Nasdaq hit a record high on Monday ahead of a big week of technology earnings reports, while the S&P 500 and the Dow industrials lagged behind as losses in healthcare heavyweight Johnson & Johnson took a toll.

2:02am IST

Nasdaq, tech shine as earnings pick up; Dow, S&P lag

NEW YORK The Nasdaq hit a record high on Monday ahead of a big week of technology earnings reports, while the S&P 500 and the Dow industrials lagged behind as losses in healthcare heavyweight Johnson & Johnson took a toll.

1:59am IST

US STOCKS SNAPSHOT-J&J weighs on Dow, S&P; Nasdaq hits record

NEW YORK, July 24 The Nasdaq hit a record high on Monday ahead of a big week of technology earnings reports, while the S&P 500 and the Dow industrials lagged behind as losses in healthcare heavyweight Johnson & Johnson took a toll.

1:32am IST

UPDATE 1-Merck, Samsung Bioepis launch discounted U.S. Remicade alternative

NEW YORK/SEOUL, July 24 Merck & Co and South Korea's Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-selling medicine.

24 Jul 2017

US STOCKS-S&P, Dow lower as Johnson & Johnson drags

* Indexes down: Dow 0.32 pct, S&P 0.21 pct, Nasdaq 0.03 pct (Adds details, changes comment, updates prices)

24 Jul 2017

BRIEF-EU Medicines Agency recommends approval J&J unit's Symtuza drug for HIV

* EU Medicines Agency recommends approval of Johnson & Johnson unit Janssen-Cilag International N.V. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Symtuza) drug for HIV Source text ID: (http://bit.ly/2vIbPPG) Further company coverage:

21 Jul 2017

UPDATE 2-China adds blockbuster drugs to insurance list after price cuts

* Gov't, drugmakers agreed price cuts of as much as 70 pct (Adds picture)

19 Jul 2017

J&J sees sales growth in near-term; raises 2017 profit forecast

Johnson & Johnson said it expects sales growth to pick up in the second half of the year on strong demand for newer, pricey treatments such as cancer drugs Darzalex and Imbruvica.

19 Jul 2017

CORRECTED-UPDATE 4-J&J sees sales growth in near-term; raises 2017 profit forecast

* Pharmaceutical sales miss estimates for third straight qtr - RBC

19 Jul 2017

J&J reports dip in quarterly profit

July 18 Johnson & Johnson, which completed its $30 billion acquisition of Swiss biotech Actelion last month, reported a 4.3 percent fall in quarterly profit, as costs rose.

18 Jul 2017

Earnings vs. Estimates